Oliver Gautschi

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
  2. ncbi request reprint Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento 95817, USA, and Clinic of Medical Oncology, University Hospital Bern, Bern, Switzerland
    Lung Cancer 55:1-14. 2007
  3. pmc The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    Phillip R Purnell
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:448-54. 2009
  4. doi request reprint MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma
    Sacha I Rothschild
    Department of Clinical Research, University of Bern, Bern, Switzerland
    J Thorac Oncol 7:1069-77. 2012
  5. doi request reprint Aurora kinases as anticancer drug targets
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Clin Cancer Res 14:1639-48. 2008
  6. ncbi request reprint Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
  7. doi request reprint Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Clin Lung Cancer 9:S129-38. 2008
  8. pmc Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
  9. doi request reprint Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer
    Sacha I Rothschild
    Department of Medical Oncology and Clinical Research, University Hospital Bern, Bern, Switzerland
    Curr Opin Oncol 23:150-7. 2011
  10. doi request reprint Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Cancer Res 68:2250-8. 2008

Detail Information

Publications18

  1. ncbi request reprint Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
    ..This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents...
  2. ncbi request reprint Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento 95817, USA, and Clinic of Medical Oncology, University Hospital Bern, Bern, Switzerland
    Lung Cancer 55:1-14. 2007
    ..To review the evidence implicating the deregulation of cyclin D1 in the pathogenesis of non-small cell lung cancer (NSCLC), and to discuss the opportunities for targeted clinical intervention...
  3. pmc The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    Phillip R Purnell
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:448-54. 2009
    ..This will facilitate the development of tests to identify patients who may benefit from these agents, allow drug activity to be monitored and rationalize the combination of these agents with other treatment modalities...
  4. doi request reprint MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma
    Sacha I Rothschild
    Department of Clinical Research, University of Bern, Bern, Switzerland
    J Thorac Oncol 7:1069-77. 2012
    ..We previously showed that ID1 is regulated by Src kinases, overexpressed in human lung adenocarcinoma, and targeted by Src-dependent microRNAs. The current study focused on the association between miR-381 and ID1 in lung adenocarcinoma...
  5. doi request reprint Aurora kinases as anticancer drug targets
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Clin Cancer Res 14:1639-48. 2008
    ..Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents...
  6. ncbi request reprint Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  7. doi request reprint Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Clin Lung Cancer 9:S129-38. 2008
    ..Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected...
  8. pmc Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
    ..This common-arm approach facilitates the prospective study of population-related pharmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated...
  9. doi request reprint Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer
    Sacha I Rothschild
    Department of Medical Oncology and Clinical Research, University Hospital Bern, Bern, Switzerland
    Curr Opin Oncol 23:150-7. 2011
    ....
  10. doi request reprint Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer
    Oliver Gautschi
    Department of Medical Oncology, Bern University Hospital, Bern, Switzerland
    Cancer Res 68:2250-8. 2008
    ..Taken together, these results reveal that Src positively interacts with the BMP-Smad-Id pathway and provide new ways for targeted inhibition of Id1...
  11. doi request reprint The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer
    Sacha I Rothschild
    University of Bern, Department Clinical Research, Bern, Switzerland
    Lung Cancer 71:306-11. 2011
    ..To substantiate this hypothesis we examined ID1, SRC and matrix metalloproteinase-9 (MMP-9) immunohistochemically in human NSCLC specimens...
  12. doi request reprint Induction chemotherapy for unresectable urothelial carcinoma of the bladder
    Pirus Ghadjar
    Department of Urology, University Hospital Bern, Bern, Switzerland
    BJU Int 107:894-7. 2011
    ..To analyse the outcome in selected patients with initially unresectable or minimally metastatic muscle-invasive urothelial bladder cancer who underwent induction chemotherapy (IC) followed by radical cystectomy (RC)...
  13. doi request reprint Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
    Henning Burmeister
    Department of Medical Oncology, University Hospital Bern, 3010, Bern, Switzerland
    Support Care Cancer 20:141-7. 2012
    ..We assessed adherence to the European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) at our institution...
  14. ncbi request reprint Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
    Oliver Gautschi
    Clinic and Policlinic of Medical Oncology, University Hospital, Freiburgstrasse 100, 3010 Bern, Switzerland
    Lung Cancer 51:303-11. 2006
    ..Here, we investigated the impact of this polymorphism on smoking-induced cancer risk and clinical outcome in patients with NSCLC stages I-IV...
  15. ncbi request reprint Early clinical trial experience with vaccine therapies in non-small-cell lung cancer
    Cheryl Ho
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Lung Cancer 9:S20-7. 2008
    ..Herein, we review the development and evolution of early lung cancer vaccine trials...
  16. ncbi request reprint Clinical development of SRC tyrosine kinase inhibitors in lung cancer
    David Lee
    CIG Media Group, LP, Dallas, TX, USA
    Clin Lung Cancer 7:381-4. 2006
    ..Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein...
  17. ncbi request reprint Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
    Oliver Gautschi
    Zurich University Hospital, Clinic and Policlinic of Oncology, Laboratory of Molecular Oncology, Haeldeliweg 4, 8044 Zurich, Switzerland
    J Clin Oncol 22:4157-64. 2004
    ..We conducted a clinical study to assess the value of circulating DNA as a prognostic marker in patients with non-small-cell lung cancer (NSCLC)...
  18. ncbi request reprint Comment on "Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-call lung cancer patients" (Cancer Letters 2003;193:207-216)
    Oliver Gautschi
    Cancer Lett 204:1. 2004